Ovid Therapeutics financials
$2.54+3.25%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $733.0K | $0.00 | $718.0K | $132.0K | $6.3M | $130.0K | $76.0K | $173.0K | $169.0K | $148.0K | $142.0K | $109.0K |
| Gross profit | $733.0K | $0.00 | $718.0K | $132.0K | $6.3M | $130.0K | $76.0K | $173.0K | $169.0K | $148.0K | $142.0K | $109.0K |
| Gross margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$15.7M | -$17.8M | -$12.3M | -$12.5M | -$5.1M | -$12.6M | -$10.7M | -$13.2M | -$20.5M | -$17.4M | -$18.2M | -$12.0M |
| Net income | -$15.0M | -$17.0M | $9.7M | -$12.2M | -$4.7M | -$10.2M | -$9.3M | -$14.0M | $8.5M | -$11.5M | -$15.3M | -$11.3M |
| Net margin | −2047.6% | — | 1345.8% | −9210.6% | −74.7% | −7873.1% | −12175.0% | −8096.0% | 5042.0% | −7764.2% | −10790.1% | −10323.9% |
| Diluted EPS | $-0.08 | $-0.12 | $0.12 | $-0.17 | $-0.06 | $-0.14 | $-0.13 | $-0.20 | $0.12 | $-0.17 | $-0.22 | $-0.16 |
| EBITDA | -$15.7M | -$17.8M | -$12.3M | -$12.5M | -$5.0M | -$12.4M | -$10.6M | -$13.1M | -$20.4M | -$17.3M | -$18.0M | -$11.9M |
| Operating cash flow | -$17.6M | -$13.9M | -$10.4M | -$12.9M | -$4.8M | -$10.3M | -$10.0M | -$15.0M | -$14.3M | -$16.7M | -$11.9M | -$10.1M |
| Free cash flow | -$17.6M | -$13.9M | -$10.4M | -$12.9M | -$4.8M | -$10.3M | -$10.0M | -$15.0M | -$14.3M | -$16.7M | -$11.9M | -$10.1M |
| Diluted shares | 197.5M | 136.2M | 81.7M | 71.1M | 71.1M | 71.0M | 70.7M | 71.0M | 71.2M | 70.7M | 70.7M | 70.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $94.1M | $13.2M | $20.6M | $28.4M | $21.1M |
| Short-term investments | $105.9M | $61.5M | $56.5M | $5.0M | $9.9M | $21.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $232.0M | $225.6M | $150.9M | $63.8M | $77.4M | $81.7M |
| Total liabilities | $22.1M | $27.4M | $20.3M | $19.1M | $21.6M | $22.4M |
| Shareholders' equity | $209.9M | $198.3M | $130.7M | $44.7M | $55.8M | $59.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology